These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8597678)

  • 1. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. Medical Research Council's General Practice Research Framework.
    BMJ; 1996 Feb; 312(7029):473-8. PubMed ID: 8597678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone therapy in women in the menopause transition. Randomised, double-blind, placebo-controlled trial of effects on body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium.
    Khoo SK; Coglan MJ; Wright GR; DeVoss KN; Battistutta D
    Med J Aust; 1998 Mar; 168(5):216-20. PubMed ID: 9539899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
    Kim CJ; Min YK; Ryu WS; Kwak JW; Ryoo UH
    Arch Intern Med; 1996 Aug 12-26; 156(15):1693-700. PubMed ID: 8694668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-year study of estrogen alone versus combined with progestin in postmenopausal women with or without hypercholesterolemia.
    Sanada M; Nakagawa H; Kodama I; Sakasita T; Ohama K
    Metabolism; 2000 Jun; 49(6):784-9. PubMed ID: 10877207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance.
    Erenus M; Karakoç B; Gürler A
    Climacteric; 2001 Sep; 4(3):228-34. PubMed ID: 11588947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate.
    Castelo-Branco C; Casals E; Sanllehy C; Duran M; Fortuny A; Vanrell JA
    J Reprod Med; 1996 Nov; 41(11):833-8. PubMed ID: 8951134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.
    Gambacciani M; Ciaponi M; Cappagli B; Genazzani AR
    Am J Obstet Gynecol; 2001 Nov; 185(5):1180-5. PubMed ID: 11717654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles.
    Barrett-Connor E; Young R; Notelovitz M; Sullivan J; Wiita B; Yang HM; Nolan J
    J Reprod Med; 1999 Dec; 44(12):1012-20. PubMed ID: 10649811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women.
    Nugent AG; Leung KC; Sullivan D; Reutens AT; Ho KK
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):690-8. PubMed ID: 14974909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
    de Kraker AT; Kenemans P; Smolders RG; Kroeks MV; van der Mooren MJ
    Eur J Obstet Gynecol Reprod Biol; 2009 Feb; 142(2):139-44. PubMed ID: 19095343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
    Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
    Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.
    Cieraad D; Conradt C; Jesinger D; Bakowski M
    Arch Gynecol Obstet; 2006 May; 274(2):74-80. PubMed ID: 16491367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
    Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
    Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen, progestogens and cardiovascular risk.
    Stefanick ML
    J Reprod Med; 1999 Feb; 44(2 Suppl):221-6. PubMed ID: 11392036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy.
    Kwok S; Selby PL; McElduff P; Laing I; Mackness B; Mackness MI; Prais H; Morgan J; Yates AP; Durrington PN; Sci FM
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):760-7. PubMed ID: 15579192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
    Meuwissen JH; Beijers-De Bie L; Vihtamaki T; Tuimala R; Siseles N; Magaril C; The HS; Houben PW; Murga M; Spielmann D; De Villiers TJ
    Gynecol Endocrinol; 2002 Apr; 16(2):155-62. PubMed ID: 12012627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.